NVAX Live signaler | Maksimer profitt med Getagraph.com

SELG 66625 min ago

@ $5.28

Utstedt: 13 mar 2024 @ 19:02

Avkastning: -22.55%

Forrige signal: mar 13 - 18:12

Forrige signal: Kjøp

Avkastning: 1.36 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs...

Stats
Dagens volum	3.01M
Gjennomsnittsvolum	7.13M
Markedsverdi	572.41M
EPS	$0 ( 2024-02-28 )
Neste inntjeningsdato	( $-1.040 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.760
ATR14	$0.00800 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Trizzino John	Buy	144 000	Restricted Stock Units
2024-03-01	O'hara Elaine	Buy	120 000	Restricted Stock Units
2024-03-01	Kelly James Patrick	Buy	176 000	Restricted Stock Units
2024-03-01	Dubovsky Filip	Buy	144 000	Restricted Stock Units
2024-03-01	Casey Mark J	Buy	12 000	Restricted Stock Units

INSIDER POWER
62.99
Last 99 transactions
Buy: 1 952 927 \| Sell: 481 828

Volum Korrelasjon

Lang: -0.13 (neutral)

Kort: -0.71 (moderate negative)

Signal:(49.895) Neutral

Novavax Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Novavax Inc Korrelasjon - Valuta/Råvare

-0.29
( neutral )

-0.27
( neutral )

0.00
( neutral )

-0.32
( neutral )

Novavax Inc Økonomi

Annual	2023
Omsetning:	$983.71M
Bruttogevinst:	$704.24M (71.59 %)
EPS:	$-5.41

FY	2023
Omsetning:	$983.71M
Bruttogevinst:	$704.24M (71.59 %)
EPS:	$-5.41

FY	2022
Omsetning:	$1.60B
Bruttogevinst:	$696.31M (43.55 %)
EPS:	$-8.42

FY	2021
Omsetning:	$1.15B
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-23.44

Financial Reports:

No articles found.

Novavax Inc

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.